These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31139854)

  • 1. [Drug treatment of Alzheimer's dementia : Status quo and perspectives].
    Müller P; Fendt M; Müller NG
    Internist (Berl); 2019 Jul; 60(7):761-768. PubMed ID: 31139854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of memantine for the treatment of dementia.
    Lo D; Grossberg GT
    Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Alzheimer's disease: current status and new perspectives.
    Scarpini E; Scheltens P; Feldman H
    Lancet Neurol; 2003 Sep; 2(9):539-47. PubMed ID: 12941576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine.
    Desmidt T; Hommet C; Camus V
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):300-6. PubMed ID: 27651011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.
    Wong CW
    Drugs Aging; 2016 Jul; 33(7):451-60. PubMed ID: 27154396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild cognitive impairment and preclinical Alzheimer's disease.
    Morris JC
    Geriatrics; 2005 Jun; Suppl():9-14. PubMed ID: 16025770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of dementia.
    Schwarz S; Froelich L; Burns A
    Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of cognitive impairment.
    von Arnim CAF; Bartsch T; Jacobs AH; Holbrook J; Bergmann P; Zieschang T; Polidori MC; Dodel R
    Z Gerontol Geriatr; 2019 Jul; 52(4):309-315. PubMed ID: 31161337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.
    Balázs N; Bereczki D; Kovács T
    Ideggyogy Sz; 2021 Nov; 74(11-12):379-387. PubMed ID: 34856086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
    Schmidt R; Hofer E; Bouwman FH; Buerger K; Cordonnier C; Fladby T; Galimberti D; Georges J; Heneka MT; Hort J; Laczó J; Molinuevo JL; O'Brien JT; Religa D; Scheltens P; Schott JM; Sorbi S
    Eur J Neurol; 2015 Jun; 22(6):889-98. PubMed ID: 25808982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying drugs in Alzheimer's disease.
    Ghezzi L; Scarpini E; Galimberti D
    Drug Des Devel Ther; 2013 Dec; 7():1471-8. PubMed ID: 24353405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
    Schölzel-Dorenbos CJ;
    Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intended pharmacotherapeutical approaches of Alzheimer's disease therapy].
    Korábecný J; Hrubá E; Soukup O; Zemek F; Musílek K; Nepovímová E; Spilovská K; Opletalová V; Kuca K
    Ceska Slov Farm; 2012 Feb; 61(1-2):4-10. PubMed ID: 22536646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of high quality trials of cognitive interventions in Alzheimer's disease.
    Huntley J; Howard R
    Int Psychogeriatr; 2016 May; 28(5):705-6. PubMed ID: 27032538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.